Lyell Immunopharma, Inc. (LYEL) DCF Valuation
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Lyell Immunopharma, Inc. (LYEL) Bundle
Explore the financial potential of Lyell Immunopharma, Inc. (LYEL) with our user-friendly DCF Calculator! Enter your projections for growth, margins, and expenses to determine the intrinsic value of Lyell Immunopharma, Inc. (LYEL) and refine your investment approach.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .7 | 7.8 | 10.7 | 84.7 | .1 | .2 | .2 | .3 | .4 | .6 |
| Revenue Growth, % | 0 | 1080.52 | 37.31 | 695.15 | -99.85 | 34.37 | 34.37 | 34.37 | 34.37 | 34.37 |
| EBITDA | -100.8 | -207.6 | -199.9 | -166.7 | -226.8 | -.2 | -.2 | -.3 | -.4 | -.6 |
| EBITDA, % | -15347.49 | -2677.19 | -1877.39 | -196.79 | -174429.23 | -100 | -100 | -100 | -100 | -100 |
| Depreciation | 4.4 | 7.5 | 14.5 | 16.5 | 20.3 | .1 | .2 | .3 | .4 | .5 |
| Depreciation, % | 667.12 | 96.38 | 136.48 | 19.45 | 15576.92 | 83.16 | 83.16 | 83.16 | 83.16 | 83.16 |
| EBIT | -105.2 | -215.1 | -214.5 | -183.1 | -247.0 | -.2 | -.2 | -.3 | -.4 | -.6 |
| EBIT, % | -16014.61 | -2773.57 | -2013.87 | -216.24 | -190006.15 | -100 | -100 | -100 | -100 | -100 |
| Total Cash | 436.0 | 612.6 | 614.8 | 640.2 | 546.2 | .2 | .2 | .3 | .4 | .6 |
| Total Cash, percent | .1 | .0 | .0 | .0 | .4 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Payable | 2.8 | 9.4 | 3.2 | 3.9 | 4.8 | .1 | .2 | .2 | .3 | .4 |
| Accounts Payable, % | 432.88 | 121.14 | 30.11 | 4.63 | 3705.38 | 66.95 | 66.95 | 66.95 | 66.95 | 66.95 |
| Capital Expenditure | -16.0 | -51.5 | -65.5 | -24.3 | -2.7 | -.1 | -.2 | -.3 | -.4 | -.5 |
| Capital Expenditure, % | -2442.47 | -663.76 | -615.06 | -28.67 | -2066.15 | -85.73 | -85.73 | -85.73 | -85.73 | -85.73 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -98.6 | -208.9 | -244.7 | -4.8 | -247.0 | -.1 | -.2 | -.2 | -.3 | -.4 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -107.4 | -246.3 | -301.9 | -11.9 | -228.5 | -4.8 | -.2 | -.2 | -.3 | -.4 |
| WACC, % | 5.05 | 5.09 | 5.13 | 3.92 | 5.13 | 4.87 | 4.87 | 4.87 | 4.87 | 4.87 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -5.4 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | -13 | |||||||||
| Present Terminal Value | -10 | |||||||||
| Enterprise Value | -16 | |||||||||
| Net Debt | -82 | |||||||||
| Equity Value | 67 | |||||||||
| Diluted Shares Outstanding, MM | 251 | |||||||||
| Equity Value Per Share | 0.27 |
What You Will Get
- Real Lyell Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures for Lyell Immunopharma, Inc. (LYEL).
- Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates specifically for Lyell.
- Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on Lyell Immunopharma’s fair value.
- Versatile Excel Template: Tailored for quick edits, scenario testing, and detailed projections related to Lyell Immunopharma, Inc. (LYEL).
- Time-Saving and Accurate: Skip building models from scratch while maintaining precision and flexibility for your Lyell analyses.
Key Features
- Comprehensive DCF Calculator: Features detailed unlevered and levered DCF valuation models tailored for Lyell Immunopharma, Inc. (LYEL).
- WACC Calculator: Pre-configured Weighted Average Cost of Capital sheet with adjustable inputs specific to LYEL.
- Customizable Forecast Assumptions: Adjust growth rates, capital expenditures, and discount rates to fit Lyell Immunopharma's projections.
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios pertinent to Lyell Immunopharma, Inc. (LYEL).
- Interactive Dashboard and Charts: Visual representations summarize essential valuation metrics for straightforward analysis.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review pre-entered Lyell Immunopharma data (historical and projected).
- Step 3: Adjust key assumptions (yellow cells) based on your analysis.
- Step 4: View automatic recalculations for Lyell Immunopharma’s intrinsic value.
- Step 5: Use the outputs for investment decisions or reporting.
Why Choose This Calculator for Lyell Immunopharma, Inc. (LYEL)?
- Comprehensive Tool: Offers DCF, WACC, and financial ratio analyses tailored for Lyell Immunopharma.
- Customizable Inputs: Modify yellow-highlighted cells to explore different investment scenarios.
- Detailed Insights: Automatically computes Lyell Immunopharma’s intrinsic value and Net Present Value.
- Preloaded Data: Historical and projected data provide reliable starting points for analysis.
- Professional Quality: Perfect for financial analysts, investors, and business consultants focused on biotechnology.
Who Should Use This Product?
- Professional Investors: Develop comprehensive and accurate valuation models for analyzing Lyell Immunopharma, Inc. (LYEL) within their portfolios.
- Corporate Finance Teams: Evaluate valuation scenarios to inform strategic decisions regarding Lyell Immunopharma, Inc. (LYEL).
- Consultants and Advisors: Deliver precise valuation insights to clients interested in Lyell Immunopharma, Inc. (LYEL).
- Students and Educators: Utilize real-world data to learn and teach financial modeling with a focus on Lyell Immunopharma, Inc. (LYEL).
- Biotech Enthusiasts: Gain insights into how biotech firms like Lyell Immunopharma, Inc. (LYEL) are valued in the stock market.
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Lyell Immunopharma historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Lyell Immunopharma, Inc. (LYEL).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.